D4Ertd196e Inhibitors
Chemical inhibitors of D4Ertd196e encompass a range of compounds that act at various points in the signaling pathways to achieve functional inhibition. LY294002 and Wortmannin are both inhibitors of phosphoinositide 3-kinases (PI3K), an essential component of the Akt signaling pathway. D4Ertd196e is a downstream effector in this pathway, and its activity is contingent upon signals propagated through PI3K-initiated phosphorylation events. By inhibiting PI3K, LY294002 and Wortmannin effectively reduce Akt phosphorylation, leading to a concomitant decrease in D4Ertd196e activity due to insufficient activation signals. Similarly, PI-103, as a multi-targeted PI3K inhibitor, not only inhibits PI3K but also DNA-PK and mTOR kinases. This broad targeting results in a wide disruption of the signaling cascades that D4Ertd196e relies upon, curtailing its function within the cell.
Additionally, Rapamycin and PP242 target the mTOR pathway, which is another critical regulator of D4Ertd196e activity. Rapamycin specifically inhibits mTORC1, while PP242 targets both mTORC1 and mTORC2 complexes. The inhibition of these complexes by these compounds disrupts the mTOR pathway's influence on various cellular processes, including those regulated by D4Ertd196e. Moving on to the MAPK/ERK pathway, PD98059, U0126, and SL327 are inhibitors of MEK1/2, which are upstream kinases necessary for the activation of ERK. The inhibition of MEK by these compounds prevents the phosphorylation and activation of ERK, leading to reduced signaling through the MAPK/ERK pathway and, therefore, decreased activity of D4Ertd196e. SB203580 contributes to the inhibition by targeting p38 MAP kinase within the MAPK pathway, further attenuating the signaling involved in stress responses that would otherwise involve D4Ertd196e. Lastly, Spautin-1, an inhibitor of ubiquitin-specific proteases, affects protein degradation pathways that indirectly modulate the signaling mechanisms controlling D4Ertd196e function. By altering the degradation rates of certain proteins, Spautin-1 can change the availability of signaling molecules necessary for D4Ertd196e activity. Together, these chemical inhibitors collectively contribute to the functional inhibition of D4Ertd196e by targeting multiple essential pathways and regulatory mechanisms within the cell.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which are upstream regulators of the Akt signaling pathway. As D4Ertd196e operates within this pathway, inhibition of PI3K leads to a reduction in Akt phosphorylation, thereby functionally inhibiting D4Ertd196e by preventing its activation and subsequent signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts by binding to the p110 subunit of PI3K, resulting in the blockade of the PI3K/Akt pathway. This blockade prevents the phosphorylation and activation of downstream targets, including D4Ertd196e, thus functionally inhibiting its role in cellular signaling processes relevant to survival and growth. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTORC1, a central component of the mTOR pathway, which is known to interact with D4Ertd196e. By inhibiting mTORC1, Rapamycin disrupts the pathway's role in protein synthesis and cell proliferation, subsequently leading to a functional inhibition of D4Ertd196e due to reduced signaling through mTORC1. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is an inhibitor of both mTORC1 and mTORC2 complexes. By inhibiting these complexes, PP242 disrupts the mTOR pathway, which is essential for various cellular functions. D4Ertd196e, being associated with this pathway, is functionally inhibited as the signaling required for its activity is suppressed through mTOR inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK/ERK pathway. As D4Ertd196e relies on signals propagated through this pathway, the inhibition of MEK by PD98059 prevents the activation of ERK, leading to a functional inhibition of D4Ertd196e due to a lack of necessary phosphorylation events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor similar to PD98059, which prevents the activation of MAPK/ERK signaling. The inhibition of MEK, and therefore the ERK pathway, functionally inhibits D4Ertd196e by disrupting the signaling mechanisms that D4Ertd196e needs to carry out its role in cell cycle regulation and proliferation. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 also targets MEK1/2 in the MAPK/ERK pathway, leading to a decrease in ERK phosphorylation. As a consequence, the activity of D4Ertd196e, which depends on the MAPK/ERK signaling, is functionally inhibited due to the lack of activation signals from the upstream kinases. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is part of the MAPK pathway. By inhibiting p38 MAP kinase, SB203580 disrupts the signaling related to stress response and apoptosis, among other processes. D4Ertd196e, being integrated into these signaling pathways, is functionally inhibited as the necessary signals are attenuated. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 is a potent inhibitor of ubiquitin-specific proteases, which can lead to altered degradation of proteins involved in various signaling pathways. Since D4Ertd196e is regulated by signals that could be modulated by protein ubiquitination, the inhibition of these proteases by Spautin-1 can lead to a functional inhibition of D4Ertd196e. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a multi-targeted PI3K inhibitor, which also targets DNA-PK and mTOR, kinases involved in the PI3K/Akt and mTOR pathways. By inhibiting these kinases, PI-103 functionally inhibits D4Ertd196e by disrupting signaling cascades that are essential for its activity, including those related to cell survival, metabolism, and growth. | ||||||